Arimidex Better Than Tamoxifen Long Term
New Option for Some Women With Early Breast Cancer
The bottom line: "Arimidex should be considered a better choice of therapy for postmenopausal women with hormone-sensitive early breast cancer."
Nevertheless, he stressed, the ultimate choice should be the patient's. "I sit down with each woman and explain the options and that there is some risk of a bone-related event. Nine in 10 women will want the newer drug. But some will want the drug that's been around 30 years."
Winer says the new data will be considered when ACOG convenes its annual expert panel on breast cancer treatment in a few months.
"Though the figures don't seem that different from a year ago [when the panel voted to keep tamoxifen as standard therapy], we have four years of experience instead of three. That means something," he said. "But will we change our recommendations? That's up to the whole panel."
In the meantime, Winer agreed. "It all comes down to sitting down with a woman, telling her everything we know about both drugs and making the decision together."